Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
Published Date: 13 Mar 2023
A new study by Sandra Amaral and her team has found that children with chronic kidney disease (CKD), regardless of disease severity,...
Read Full NewsPhase 3b study revealed Itvisma's safety and efficacy in treating spinal muscular atrophy, showing modest motor function improvements in patients previously on other therapies.
FDA Approves Nerandomilast (Jascayd) Tablets for Progressive Pulmonary Fibrosis
Renal Transplantation May Lower Sleep Disorder Risk Versus Dialysis
BMI, Inflammatory Bowel Disease Both Show Causal Effect on HS Development
The HCPFive: Top News for Healthcare Providers from the Week of 12/14
1.
Antitumor cell activity in glioblastoma is controlled by blocking the triggering receptor expressed on myeloid cells 2.
2.
Momelotinib, a JAK inhibitor, has FDA approval to treat adult myelofibrosis in anemic patients.
3.
MCh in Gynecologic Oncology: Admission, Medical School, Fees, Qualifications Information
4.
Immune cell homing hydrogel-based platform captures dendritic cells to process mRNA from cancer vaccines
5.
COVID-19 mRNA vaccines could unlock the next revolution in cancer treatment
1.
Advancements in Cancer Treatment and Survival Outcomes for Acute Myeloid Leukemia
2.
Integrative Clinical Genomics of Metastatic Cancer: Decoding Tumor Evolution for Precision Oncology
3.
Unraveling the Mysteries of Hematocrit: How It Impacts Your Health
4.
What is Hemorrhagic Cystitis and How to Manage its Symptoms
5.
Revolutionizing Cancer Treatment with Darzalex: How an Innovative Drug is Transforming Lives
1.
International Lung Cancer Congress®
2.
Future NRG Oncology Meeting
3.
Genito-Urinary Oncology Summit 2026
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Pazopanib Takes Center Stage in Managing Renal Cell Carcinoma - Part V
2.
Guideline Recommendations of Lorlatinib as First-Line Treatment for ALK+ NSCLC
3.
From Relapse to Remission Mapping the Treatment Journey in Adult R R B Cell ALL The Critical Goal of MRD
4.
The Reign of the CROWN Trial and the Dawn of a New Era in Frontline Management- Further Discussion
5.
Exploring Potentials of Lorlatinib: The Third Generation ALK-TKI Through CROWN Trial
Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
© Copyright 2025 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
To get started please enter your email ID
Join to enhance your clinical skills and gain specialized in-depth medical knowledge